{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:18:53Z","timestamp":1787800733744,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,16]]},"DOI":"10.1038\/s41416-025-03164-5","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:29:50Z","timestamp":1756358990000},"page":"1297-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-4973","authenticated-orcid":false,"given":"Alexej","family":"Ballhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-0137","authenticated-orcid":false,"given":"Arndt","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Jay","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-5743","authenticated-orcid":false,"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel Helga Sophie","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Carlotta","family":"Pircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Jarosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Andena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-6788","authenticated-orcid":false,"given":"Annika","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Alessandra","family":"Chiaramonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik Paul","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-2899","authenticated-orcid":false,"given":"Alessandra","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"3164_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"3164_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713\u201329.","journal-title":"Ann Oncol"},{"key":"3164_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103677","volume":"9","author":"AHS Alig","year":"2024","unstructured":"Alig AHS, Modest DP, Stintzing S, Heinrich K, Geissler M, Fischer von Weikersthal L, et al. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. ESMO Open. 2024;9:103677.","journal-title":"ESMO Open"},{"key":"3164_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","volume":"184","author":"D Rossini","year":"2023","unstructured":"Rossini D, Boccaccino A, Carullo M, Antoniotti C, Dima G, Ciraci P, et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer. 2023;184:106\u201316.","journal-title":"Eur J Cancer"},{"key":"3164_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"3164_CR6","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol. 2017;28:3009\u201314.","journal-title":"Ann Oncol"},{"key":"3164_CR7","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J Clin Oncol. 2019;37:3099\u2013110.","journal-title":"J Clin Oncol"},{"key":"3164_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00037","volume":"6","author":"G Randon","year":"2022","unstructured":"Randon G, Maddalena G, Germani MM, Pircher CC, Manca P, Bergamo F, et al. Negative ultraselection of patients with RAS\/BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy. JCO Precis Oncol. 2022;6:e2200037.","journal-title":"JCO Precis Oncol"},{"key":"3164_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-23-3023","volume":"30","author":"A Stahler","year":"2024","unstructured":"Stahler A, Kind AJ, Sers C, Mamlouk S, Muller L, Karthaus M, et al. Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212). Clin Cancer Res. 2024;30:1256\u201363.","journal-title":"Clin Cancer Res"},{"key":"3164_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394\u2013400.","journal-title":"J Clin Oncol"},{"key":"3164_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","volume":"17","author":"E Diaz-Rubio","year":"2012","unstructured":"Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17:15\u201325.","journal-title":"Oncologist"},{"key":"3164_CR12","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"B Chibaudel","year":"2009","unstructured":"Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727\u201333.","journal-title":"J Clin Oncol"},{"key":"3164_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","volume":"12","author":"RA Adams","year":"2011","unstructured":"Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12:642\u201353.","journal-title":"Lancet Oncol"},{"key":"3164_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","volume":"15","author":"H Wasan","year":"2014","unstructured":"Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15:631\u20139.","journal-title":"Lancet Oncol"},{"key":"3164_CR15","doi-asserted-by":"publisher","first-page":"e2333533","DOI":"10.1001\/jamanetworkopen.2023.33533","volume":"6","author":"V Boige","year":"2023","unstructured":"Boige V, Blons H, Francois E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, et al. Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Netw Open. 2023;6:e2333533.","journal-title":"JAMA Netw Open"},{"key":"3164_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, et al. Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1268\u201375.","journal-title":"JAMA Oncol"},{"key":"3164_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2019.07.006","volume":"119","author":"Y Munemoto","year":"2019","unstructured":"Munemoto Y, Nakamura M, Takahashi M, Kotaka M, Kuroda H, Kato T, et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019;119:158\u201367.","journal-title":"Eur J Cancer"},{"key":"3164_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.21.01332","volume":"40","author":"DP Modest","year":"2022","unstructured":"Modest DP, Karthaus M, Fruehauf S, Graeven U, Muller L, Konig AO, et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212). J Clin Oncol. 2022;40:72\u201382.","journal-title":"J Clin Oncol"},{"key":"3164_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/fon-2017-0592","volume":"14","author":"C Pinto","year":"2018","unstructured":"Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, et al. Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. Future Oncol. 2018;14:1339\u201346.","journal-title":"Future Oncol"},{"key":"3164_CR20","doi-asserted-by":"crossref","unstructured":"Avallone A, Giuliani F, De Stefano A, Santabarbara G, Nasti G, Montesarchio V, et al. Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. J Clin Oncol. 2025;43:829\u201339.","DOI":"10.1200\/JCO.24.00979"},{"key":"3164_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112945","volume":"190","author":"A Raimondi","year":"2023","unstructured":"Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, et al. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. Eur J Cancer. 2023;190:112945.","journal-title":"Eur J Cancer"},{"key":"3164_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113975","volume":"202","author":"T Yoshino","year":"2024","unstructured":"Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, et al. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer. 2024;202:113975.","journal-title":"Eur J Cancer"},{"key":"3164_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2023;329:1271\u201382.","journal-title":"JAMA"},{"key":"3164_CR24","doi-asserted-by":"crossref","unstructured":"Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024;30:730\u20139.","DOI":"10.1038\/s41591-023-02791-w"},{"key":"3164_CR25","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-20-2748","volume":"26","author":"A Stahler","year":"2020","unstructured":"Stahler A, Stintzing S, Modest DP, Ricard I, Giessen-Jung C, Kapaun C, et al. Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer: combined analysis of three randomized trials. Clin Cancer Res. 2020;26:6559\u201367.","journal-title":"Clin Cancer Res"},{"key":"3164_CR26","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1158\/1078-0432.CCR-23-0859","volume":"29","author":"CJM Williams","year":"2023","unstructured":"Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, et al. Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. Clin Cancer Res. 2023;29:4153\u201365.","journal-title":"Clin Cancer Res"},{"key":"3164_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","volume":"101","author":"E Aranda","year":"2018","unstructured":"Aranda E, Garcia-Alfonso P, Benavides M, Sanchez Ruiz A, Guillen-Ponce C, Safont MJ, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer. 2018;101:263\u201372.","journal-title":"Eur J Cancer"},{"key":"3164_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1200\/JCO.23.01021","volume":"42","author":"C Pinto","year":"2024","unstructured":"Pinto C, Orlandi A, Normanno N, Maiello E, Calegari MA, Antonuzzo L, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab versus cetuximab as maintenance therapy in first-line therapy for RAS and BRAF wild-type metastatic colorectal cancer: phase III ERMES study. J Clin Oncol. 2024;42:1278\u201387.","journal-title":"J Clin Oncol"},{"key":"3164_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103628","volume":"9","author":"A Ballhausen","year":"2024","unstructured":"Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Muller L, Konig AO, et al. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial. ESMO Open. 2024;9:103628.","journal-title":"ESMO Open"},{"key":"3164_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112955","volume":"190","author":"A Ballhausen","year":"2023","unstructured":"Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Muller L, Konig AO, et al. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. Eur J Cancer. 2023;190:112955.","journal-title":"Eur J Cancer"},{"key":"3164_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2020.04.048","volume":"135","author":"A Raimondi","year":"2020","unstructured":"Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, et al. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: a pre-specified secondary analysis of the Valentino study. Eur J Cancer. 2020;135:230\u20139.","journal-title":"Eur J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03164-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:43:59Z","timestamp":1761774239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,16]]}},"alternative-id":["3164"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03164-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB: Stock and other ownership interests: BioNTech SE. Honoraria: Amgen. Research funding: Amgen (Inst). Travel, Accommodations, Expenses: Amgen. FM: Honoraria from Pierre Fabre and Servier; research grants from Incyte (to their institution); travel grants from Amgen and Pierre Fabre. AS: Honoraria: Roche, Servier, Taiho Pharmaceutical. Consulting or advisory role: Bristol Myers Squibb\/Pfizer, Novocure. Travel, Accommodations, Expenses: Amgen, Roche, Lilly, Pfizer. SL: Participation in advisory boards for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Servier, Takeda, Rottapharm, and Beigene; personal honoraria as invited speaker from Amgen, AstraZeneca, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre Fabre, Roche, and Servier; research funding (to their institution) from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Hutchinson, Incyte, Merck Serono, Mirati, MSD, Pfizer, Roche, and Servier. AJK: No competing interests declared. CC: Advisory board or consultant role with Astra Zeneca, Bicara Therapeutics, BMS, GSK, Lilly, Merck, Mirati, MSD, Nordic Pharma, Roche, Pfizer, Pierre Fabre, Revolution Medicine, Rottapharm, Takeda, Tempus; Invited speaker with compensation for Amgen, Bayer, Merck Serono, MSD, Pierre Fabre Servier, Takeda; Research grants by Amgen, Merck, Pierre Fabre, Roche, Seagen (Pfizer), Servier, Tempus. SS: No competing interests declared. GR: No competing interests declared. DH: No competing interests declared. MP: No competing interests declared. AHSA: Honoraria: MSD. Travel, Accommodations, Expenses: Merck, BMS GmbH and Co. KG. CCP: No competing interests declared. AJ: No competing interests declared. PA: No competing interests declared. Annika Kurreck: Honoraria: Taiho Pharmaceutical, Amgen, Servier. Travel, Accommodations, Expenses: medac, Amgen, Servier. AAC: No competing interests declared. SS: Honoraria: Merck KGaA, Roche, Amgen, Servier, MSD, Pfizer, Pierre Fabre, Bristol Myers Squibb GmbH, Nordic Bioscience, AstraZeneca. Consulting or advisory role: Merck Kgaa, Roche, Amgen, Pierre Fabre, MSD, AstraZeneca, Servier, GlaxoSmithKline, Terumo, Nordic Bioscience, Seagen. Research Funding: Pierre Fabre (Inst), Roche Molecular Diagnostics (Inst), Merck Serono (Inst), Amgen (Inst). Travel, Accommodations, Expenses: Merck KGaA, Roche, Sanofi, Bayer, Sirtex Medical, Amgen, Lilly, Takeda, Pierre Fabre, AstraZeneca. FP: Research funding (to their institution) from Lilly, Bristol-Myers Squibb, Incyte, AstraZeneca, Amgen, and Agenus; personal honoraria as an invited speaker from BeiGene, Daiichi Sankyo, Seagen, Astellas, Ipsen, AstraZeneca, Servier, Bayer, Takeda, Johnson & Johnson, Bristol-Myers Squibb, MSD, Amgen, Merck Serono, Pierre Fabre; and advisory or consultancy fees from Bristol-Myers Squibb, MSD, Amgen, Pierre Fabre, Johnson & Johnson, Servier, Bayer, Takeda, Astellas, GSK, Daiichi Sankyo, Pfizer, BeiGene, Jazz Pharmaceuticals, Incyte, Rottapharm, and Merck Serono. DPM: Honoraria: Merck Serono, Amgen, Servier, Bristol Myers Squibb, Taiho Pharmaceutical, Merck Sharp and Dohme, Pierre Fabre, Onkowissen, Sanofi, Lilly, AstraZeneca\/MedImmune, Incyte, Takeda. Consulting or advisory role: Merck Serono, Amgen, Merck Sharp and Dohme, Roche, Servier, Incyte, Bristol Myers Squibb, Pierre Fabre, Lilly, Cor2Ed, IQVIA, Onkowissen. Research funding: Amgen (Inst), Servier (Inst). Travel, Accommodations, Expenses: Amgen, Merck Serono, Servier. AR: Honoraria for speaker bureau or advisory board participation from Servier and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocols and its amendments were approved by an independent institutional review board or ethics committee at each study site. The study was conducted in compliance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written, informed consent. This secondary analysis is part of an IPD pooled analysis study and was approved by the ethical committee of Fondazione IRCCS Istituto Nazionale dei Tumori (Identifier: INT 99\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}